Medicamen Biotech Limited (MEDICAMEQ) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Medicamen Biotech Limited stock ₹117, price ₹293, that is 60.1% below the price, quality 42 out of 100. Rating: strongly overvalued. Calculated from audited financials with 17 of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Medicamen Biotech Limited
MEDICAMEQ · NSEFar too expensive (fair value 60% below the price), weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 13, 2026.
How to read this chart
60‑month range ₹219.88 – ₹1,192 · fair‑value band ₹81.82 – ₹138.17 · the ₹293.15 price screens above the ₹116.89 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 13, 2026.
Every Wednesday you see whether Medicamen Biotech is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Medicamen Biotech Limited, a pharmaceutical company, research, develops, manufactures, markets, sells, and distributes pharmaceutical formulations in India and internationally. The company offers drugs in various forms, including tablet, capsule, syrups, oral solution, and drops.
Show moreShow less
Its products are used in therapeutic areas comprising cancer care, cardiology, CNS, diabetology, anti-infective, anti-malarials, vitamins, antibiotics, and supplements, other generics, and pain management. The company was incorporated in 1993 and is based in New Delhi, India.
Stock analysis
Medicamen Biotech Limited (MEDICAMEQ) currently trades at ₹293.15, while our model-based Fair Value estimate is ₹116.89, 60% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of ₹149.62 per share, and 1 of the 17 models we run sit above the ₹293.15 price.
Bear case: the Dividend Discount group reads lowest at ₹12.80, and 16 of the 17 models stay below the price. Data coverage for this calculation is high.
Scenario range: ₹81.82 (bear) to ₹138.17 (bull), the price of ₹293.15 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Medicamen Biotech Limited reported revenue of ₹2.0B in FY2026 versus ₹1.2B in FY2022, a compound +14.4%/yr. Reported net income was ₹96.4M in FY2026, compounding −10.3%/yr from FY2022.
Key figures
Market cap ₹3.9B (≈ $41.5M) Micro · P/E ratio 39.6 · P/S ratio 1.83 · EPS (TTM) ₹7.41 · Dividend yield 0.3% · Net margin 4.7% · Return on equity 4.0% · Return on assets (EBIT) 7.6% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 33 out of 100 (medium confidence).
What moves the price
The share trades about 30% below its 52-week high and 33% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −60%, MEDICAMEQ screens richer than that median.
Fair Value models
All 17 models by family
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
MEDICAMEQ screens overvalued: fair value 60% below the price. Compare with Merck KGaA →
Compare Medicamen Biotech Limited with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 604 stocks
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Dividend yield by industry
- EV/EBITDA by industry
- Stock screener with 62 metrics
- Undervalued stocks: Indian Stocks
- Valuation of the India market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Zoetis Inc ZTS | $83.82 | $113.53 | +35% | vs MEDICAMEQ |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥48.07 | ¥53.04 | +10% | vs MEDICAMEQ |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,880 | ₹1,983 | +5% | vs MEDICAMEQ |
| Haleon plc HLN | $9.17 | $8.47 | −8% | vs MEDICAMEQ |
| Merck KGaA MRK | €149.60 | €108.83 | −27% | vs MEDICAMEQ |
| Galderma Group GALD | CHF 191.40 | CHF 112.30 | −41% | vs MEDICAMEQ |
| Takeda Pharmaceutical Company TAK | $21.43 | $11.20 | −48% | vs MEDICAMEQ |
| Sandoz Group SDZ | CHF 84.60 | CHF 40.54 | −52% | vs MEDICAMEQ |
| Teva Pharmaceutical Industries Limited TEVA | $44.50 | $20.74 | −53% | vs MEDICAMEQ |
| Divi's Laboratories Limited DIVISLAB | ₹11,442 | ₹1,567 | −86% | vs MEDICAMEQ |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Medicamen Biotech Limited (MEDICAMEQ) overvalued or undervalued?
What is the fair value of MEDICAMEQ?
What is the quality score of MEDICAMEQ?
What is the price target for Medicamen Biotech Limited (MEDICAMEQ)?
What is the Medicamen Biotech Limited stock forecast for 2026?
What is the revenue of Medicamen Biotech Limited (MEDICAMEQ)?
Does Medicamen Biotech Limited pay a dividend?
How much is the dividend of Medicamen Biotech Limited (MEDICAMEQ) and when is the ex-dividend date?
What is the intrinsic value of Medicamen Biotech Limited (MEDICAMEQ)?
Is Medicamen Biotech Limited stock overvalued or undervalued in 2026?
Is fair value the same as the market price of MEDICAMEQ?
How much is Medicamen Biotech Limited worth?
What do the bullish and bearish scenarios say about MEDICAMEQ?
What is the P/E ratio of MEDICAMEQ?
How solid is the balance sheet of Medicamen Biotech Limited (MEDICAMEQ)?
How far is MEDICAMEQ from its 52-week high?
Which stocks are comparable to Medicamen Biotech Limited?
Is Medicamen Biotech Limited stock attractive at the current price?
How is the fair value of MEDICAMEQ calculated?
Is it still worth investing in stocks now?
What is the share price of Medicamen Biotech Limited (MEDICAMEQ)?
What should I pay attention to with Medicamen Biotech Limited right now?
Where does the earnings growth of Medicamen Biotech Limited (MEDICAMEQ) come from?
Key figures of Medicamen Biotech Limited
How large is the market capitalisation of Medicamen Biotech Limited (MEDICAMEQ)?
What is the P/S ratio of Medicamen Biotech Limited (MEDICAMEQ)?
What are the earnings per share of Medicamen Biotech Limited (MEDICAMEQ)?
What is the dividend yield of Medicamen Biotech Limited (MEDICAMEQ)?
What is the net margin of Medicamen Biotech Limited (MEDICAMEQ)?
What is the return on equity of Medicamen Biotech Limited (MEDICAMEQ)?
What is the EBIT return on assets of Medicamen Biotech Limited (MEDICAMEQ)?
What is the operating margin of Medicamen Biotech Limited (MEDICAMEQ)?
How fast is revenue growing at Medicamen Biotech Limited (MEDICAMEQ)?
How fast are earnings growing at Medicamen Biotech Limited (MEDICAMEQ)?
How much free cash flow does Medicamen Biotech Limited (MEDICAMEQ) generate?
How much net debt does Medicamen Biotech Limited (MEDICAMEQ) carry?
Watch Medicamen Biotech Limited in the live analysis
One click puts Medicamen Biotech Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.